The latest results from an ongoing study involving more than 800 participants with age-related macular degeneration confirm the complexity of the disease.

Retina Implant AG is testing its device in three countries and hoping to expand its human study to the United States.

Results from a recent study reveal that people with high levels of a specific protein are more likely to contract age-related macular degeneration.

Designed for people with advanced retinitis pigmentosa, the “Argus II” will be available in the United States later this year.